Myovant Sciences
2000 Sierra Point Parkway, Suite 900
Brisbane, CA 94005
United States
Tel: 650-392-0222
Website: https://www.myovant.com/
About Myovant Sciences
We aspire to be the leading healthcare company focused on redefining care for women’s health and prostate cancer. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer. We strive to improve the lives of millions of people, while building an innovative, dynamic, and collaborative company where employees thrive.
136 articles with Myovant Sciences
-
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
5/10/2022
Myovant Sciences announced financial results for the fourth fiscal quarter and fiscal year ended March 31, 2022 and provided other corporate updates.
-
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
5/9/2022
Myovant Sciences and Accord Healthcare, Ltd. announced that they have entered into an exclusive license agreement for Accord to commercialize relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey, with the right of first negotiation if Myovant decides to enter into licensing arrangements in countries in the Middle East, Africa and India.
-
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
5/6/2022
Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application for MYFEMBREE® for the management of moderate to severe pain associated with endometriosis.
-
The FDA has extended the review period for Myfembree, following the supplemental New Drug Application from Pfizer and Myovant. Here's more about this news.
-
As May gets off to a slow start for the FDA calendar, a few companies have important target action dates.
-
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
4/29/2022
Myovant Sciences (NYSE: MYOV) today announced that the European Commission (EC) has approved the marketing authorisation application for ORGOVYX® (relugolix, 120 mg) for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
-
Myovant said that the FDA provided notice it had found deficiencies that will preclude any potential discussion of labeling or post-marketing requirements at this time.
-
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
4/12/2022
Myovant Sciences and Pfizer announced an update on the Supplemental New Drug Application for MYFEMBREE® for the management of moderate to severe pain associated with endometriosis.
-
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
2/25/2022
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the approval of ORGOVYX® (relugolix, 120 mg) for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
-
Myovant Sciences to Present at Upcoming Investor Conferences - Feb 07, 2022
2/7/2022
Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., and other members of the Myovant executive team will participate in a fireside chat at the following investor conferences:
-
Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates
1/26/2022
Third fiscal quarter 2021 total revenues of $54.4 million, including net product revenue of $29.3 million Net product revenue from U.S. sales of ORGOVYX ® of $24.4 million.
-
Myovant Sciences to Host Third Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on January 26, 2022
1/12/2022
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its third fiscal quarter 2021, ended December 31, 2021.
-
Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021
1/10/2022
Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced preliminary financial results for the third quarter of fiscal year 2021.
-
Myovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/3/2022
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., will present at the 40th Annual J.P. Morgan Healthcare Conference.
-
Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference
11/23/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021.
-
Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors
11/8/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced the appointment of Nancy Valente, M.D. as an independent member of the company’s Board of Directors.
-
Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates
10/26/2021
Myovant SciencesMyovant Sciences, a healthcare company focused on redefining care for women and for men, announced financial results for the second quarter of fiscal year 2021 and other corporate updates.
-
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
10/19/2021
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the presentation of new data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in premenopausal women with uterine fibroids and in women with endometriosis pain (an investigational use).
-
Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021
10/12/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter 2021, ended September 30, 2021.
-
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
9/9/2021
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis.